摘要
目的观察瑞舒伐他汀对原发性高血压合并高脂血症血脂和动脉粥样硬化的影响。方法 2009年9月~2010年9月,98例原发性高血压合并高脂血症患者随机分为两组,对照组49例采用常规治疗,观察组49例在常规治疗的基础上加用瑞舒伐他汀,比较观察两组的血脂和动脉粥样硬化的变化。结果与治疗前比较,观察组治疗后TC、TG、LDL-C水平明显下降(P<0.05),HDL-C水平明显升高(P<0.05),而对照组无明显变化(P>0.05)。并且,观察组治疗后TC、TG、LDL-C水平均明显低于同期对照组,HDL-C水平明显高于对照组,两组比较差异有统计学意义(P<0.05)。与治疗前比较,观察组治疗后LN和LMT水平明显下降(P<0.05),而对照组无明显变化(P>0.05)。观察组治疗后LN和LMT水平均明显低于同期对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀对原发性高血压合并高脂血症患者进行治疗,能够明显降低血脂,缓解动脉粥样硬化,值得临床推广应用。
Objective To observe the affection of rosuvastatin on blood fat and arteriosclerotic plaque in patients with hy- pertension and hypedipoidemia. Methods From September 2009 to September 2010, 98 cases of hypertensive with hyperlipoi- detain patients were randomly separated into two groups, which observation group with 49 cases was treated with rosuvastatin at basis of normal therapy. The changes of blood fat and arteriosclerotic plaque before and after treatment were observed. Results Compared with pre-treatment, the levels of TC, TG and LDL-C were significantly decreased, and HDL-C was significantly in- creased in observation group( P 〈 0. 05 ), while no significant difference in control group (P 〉 0. 05 ). Moreover, the levels of TC, TG and LDL-C in observation group were significantly lower than those in comrol group, HDL-C was significantly higher than that in control group(P 〈0. 05). Compared with pre-treatment, the levels of LN and LMT were significantly decreased in observation group ( P 〈 0.05 ), while no significant difference in control group ( P 〉 0. 05 ). Moreover, the levels of LN and LMT in observation group were significantly lower than those in control group( P 〈 0.05 ). The levels of LN and LMT were no significant differences in control group before and after treatment ( P 〉 0. 05 ). Conclusion Rosuvastatin in treatment with patients with hypertension and hyperlipoidemia can low blood fat and arteriosclerotic plaque, which can be applied in clinic.
出处
《四川医学》
CAS
2011年第12期1959-1961,共3页
Sichuan Medical Journal